VJHemOnc is committed to improving our service to you

ASH 2019 | Phase 2 NFKB2 rearrangement-driven MM trial: predictor of sensitivity to PIs?

VJHemOnc is committed to improving our service to you

Sagar Lonial

Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, covers the phase 2 trial of ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFKB2 rearrangement (NCT02765854). This aimed to use NFKB2 status as a biomarker to predict for sensitivity to proteasome inhibitors (PIs). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter